630 related articles for article (PubMed ID: 24076117)
1. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
Tettamanti S; Magnani CF; Biondi A; Biagi E
Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
[TBL] [Abstract][Full Text] [Related]
2. The progress and current status of immunotherapy in acute myeloid leukemia.
Yang D; Zhang X; Zhang X; Xu Y
Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
[TBL] [Abstract][Full Text] [Related]
3. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
[TBL] [Abstract][Full Text] [Related]
4. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy in acute myeloid leukemia.
Arpinati M; Curti A
Immunotherapy; 2014; 6(1):95-106. PubMed ID: 24341888
[TBL] [Abstract][Full Text] [Related]
6. Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.
Greiner J; Döhner H; Schmitt M
Haematologica; 2006 Dec; 91(12):1653-61. PubMed ID: 17145602
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic strategies for relapse control in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Hellstrand K
Blood Rev; 2013 Sep; 27(5):209-16. PubMed ID: 23871358
[TBL] [Abstract][Full Text] [Related]
9. Antibody therapy for acute myeloid leukaemia.
Gasiorowski RE; Clark GJ; Bradstock K; Hart DN
Br J Haematol; 2014 Feb; 164(4):481-95. PubMed ID: 24321020
[TBL] [Abstract][Full Text] [Related]
10. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
11. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
[TBL] [Abstract][Full Text] [Related]
13. Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Sommaggio R; Cappuzzello E; Dalla Pietà A; Tosi A; Palmerini P; Carpanese D; Nicolè L; Rosato A
Oncoimmunology; 2020 Jun; 9(1):1777046. PubMed ID: 32923140
[TBL] [Abstract][Full Text] [Related]
14. A novel nonradioactive CFDA assay to monitor the cellular immune response in myeloid leukemia.
Yang T; Chen ZZ; Kolb HJ; Buhmann R
Immunobiology; 2013 Apr; 218(4):548-53. PubMed ID: 22883564
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in acute myeloid leukemia.
Grosso DA; Hess RC; Weiss MA
Cancer; 2015 Aug; 121(16):2689-704. PubMed ID: 26095886
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
Rotiroti MC; Buracchi C; Arcangeli S; Galimberti S; Valsecchi MG; Perriello VM; Rasko T; Alberti G; Magnani CF; Cappuzzello C; Lundberg F; Pande A; Dastoli G; Introna M; Serafini M; Biagi E; Izsvák Z; Biondi A; Tettamanti S
Mol Ther; 2020 Sep; 28(9):1974-1986. PubMed ID: 32526203
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.
Majeti R
Oncogene; 2011 Mar; 30(9):1009-19. PubMed ID: 21076471
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML.
Korver W; Zhao X; Singh S; Pardoux C; Zhao J; Guzman ML; Sen S; Yonkovich S; Liu S; Zhan X; Tomasevic N; Zhou C; Gros D; Jordan CT; Gotlib J; Hsi ED; Abo A
Leukemia; 2009 Sep; 23(9):1587-97. PubMed ID: 19440216
[TBL] [Abstract][Full Text] [Related]
19. Advances in immunotherapy for pediatric acute myeloid leukemia.
Bonifant CL; Velasquez MP; Gottschalk S
Expert Opin Biol Ther; 2018 Jan; 18(1):51-63. PubMed ID: 28945115
[TBL] [Abstract][Full Text] [Related]
20. Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies.
Rotiroti MC; Arcangeli S; Casucci M; Perriello V; Bondanza A; Biondi A; Tettamanti S; Biagi E
Hum Gene Ther; 2017 Mar; 28(3):231-241. PubMed ID: 27967241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
